Ugrás a tartalomra
Merck

MAB8702

Sigma-Aldrich

Anti-Dengue Virus Type II Antibody, clone 3H5-1

clone 3H5-1, Chemicon®, from mouse

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

UNSPSC kód:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biológiai forrás

mouse

Minőségi szint

antitest forma

purified immunoglobulin

klón

3H5-1, monoclonal

faj reaktivitás

human

gyártó/kereskedő neve

Chemicon®

technika/technikák

immunofluorescence: suitable
inhibition assay: suitable (hemagglutination)

izotípus

IgG1

kiszállítva

wet ice

Általános leírás

Dengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.

Egyediség

Reacts with the Dengue type 2 virus.

Immunogén

Dengue type 2 antigen (New Guinea C).

Alkalmazás

Recommended for use in an immunofluorescent assay. Also suitable for use in hemagglutination-inhibition tests and plaque-reduction assays.

IFA: 1:200-1:400.

Dilute with buffer pH 7.5-8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used.

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
This Anti-Dengue Virus Type II Antibody, clone 3H5-1 is validated for use in HI, IF for the detection of Dengue Virus Type II.

Fizikai forma

Format: Purified
Protein G Purified
Protein G Purified immunoglobulin. Liquid in 0.02 M PB, 0.25 M NaCl, pH = 7.6 with 0.1% Na Azide as a preservative

Tárolás és stabilitás

Maintain at 2°C to 8°C in undiluted aliquots for up to 12 months after date of receipt.

Analízis megjegyzés

Control
Dengue positive patient sample

Egyéb megjegyzések

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Jogi információk

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Jogi nyilatkozat

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Tárolási osztály kódja

10 - Combustible liquids

WGK

WGK 2

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking.
van der Schaar, HM; Rust, MJ; Waarts, BL; van der Ende-Metselaar, H; Kuhn, RJ; Wilschut et al.
Journal of virology null
Sialic acid expression in the mosquito Aedes aegypti and its possible role in dengue virus-vector interactions.
Cime-Castillo, J; Delannoy, P; Mendoza-Hernandez, G; Monroy-Martinez, V; Harduin-Lepers et al.
BioMed Research International null
Leticia Franco et al.
PLoS neglected tropical diseases, 5(8), e1251-e1251 (2011-08-11)
Dengue virus (DENV) circulates in human and sylvatic cycles. Sylvatic strains are both ecologically and evolutionarily distinct from endemic viruses. Although sylvatic dengue cycles occur in West African countries and Malaysia, only a few cases of mild human disease caused
Rodrigo Guabiraba et al.
European journal of immunology, 43(6), 1529-1544 (2013-03-19)
Dengue virus (DENV), a mosquito-borne flavivirus, is a public health problem in many tropical countries. IL-22 and IL-17A are key cytokines in several infectious and inflammatory diseases. We have assessed the contribution of IL-22 and IL-17A in the pathogenesis of
Zhi-Shan Zhang et al.
Molecular medicine reports, 11(2), 1009-1016 (2014-11-06)
There is currently no effective vaccine to prevent dengue infection, despite the existence of multiple studies on potential methods of immunization. The aim of the present study was to explore the effect of DNA and/or recombinant protein on levels of

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással